Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
Pamela Farrell(Takeda (United States)), Ron de Jong(Takeda (United States)), Lihong Shi(Sichuan Cancer Hospital), Petro Halkowycz(Takeda (United States)), Sarah Elliott(United States Geological Survey), Charles E. Grimshaw(Takeda (United States)), Jennifer Matuszkiewicz(Takeda (United States)), Bi‐Ching Sang(Takeda (United States)), Seigo Ishino(Takeda (United States)), Bheema Paraselli(Takeda (United States)), Lilly Zhang(Takeda (United States)), Bumsup Lee(Takeda (United States)), Mika Teratani(Takeda (United States)), Takashi Hoshino(Takeda (United States)), Toshiyuki Nomura(Mitsubishi Group (Japan)), Yoshikazu Ohta(University of Miyazaki), Deepika Balakrishna(Takeda (United States)), Takashi Satou(Takeda (Japan)), Robyn Fabrey(Takeda (United States))
Cited by 46
Related Papers
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size
|Molecular and Cellular Biology|2005|549
Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
|Journal of Biological Chemistry|2011|441
Potent and selective inhibitors of Akt kinases slow the progress of tumors <i>in vivo</i>
|Molecular Cancer Therapeutics|2005|244